Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-7

Low monocytes shows a huge improvement and under65 is significant.
I don’t think the market fully appreciates these results and the monetary potential. Everyone is looking for the silver bullet, when the reality is different bullets for different patient groups.
At a minimum, if Efti increases life expectancy by nearly two years in 20% of mbc patients and providing better quality of life then it’s a BLOCKBUSTER drug. No ifs-or buts.

And that is only scratching the surface of Efti potential.

I’ll be referring to Efti as a blockbuster in the making from now on.